Articles tagged "Kidney transplantation"

2017 American Transplant Congress
Outcomes of Hand Assisted Laparoscopic Right Donor Nephrectomy, Single Center Experience.
A. El-Hinnawi, A. Rajab, R. Pelletier.
Transplant Surgery, The Ohio State Wexner Medical Center, Columbus, OH
Right donor nephrectomy,especially when conducted laparoscopically,has not been accepted by most transplant surgeons because of the consequent short right renal vein and the possible increased…
2017 American Transplant Congress
Release of HMGB1 in Serum and Urine of Brain-Death Donors Is Associated with Delayed Graft Function (DGF) of the Kidney.
A. Zmijewska,¹ J. Chen,¹ J. Locke,² J. Zmijewski,¹ R. Mannon.¹
¹Medicine, University of Alabama at Birmingham, Birmingham, AL; ²Surgery, University of Alabama at Birmingham, Birmingham, AL
Delayed kidney graft function (DGF) following a kidney transplant is associated with worse graft survival and higher rejection risk. Risk factors for DGF have been…
2017 American Transplant Congress
Analysis of Outcomes in High Risk Kidney Transplants.
E. Liu, M. Aull, J. Lee, S. Kapur.
Kidney and Pancreas Transplantation, NewYork-Presbyterian Weill Cornell Medical Center, New York, NY
Background: The new kidney allocation system implemented in 12/2014 utilizes estimated post-transplant survival scores (EPTS) and kidney donor profile index (KDPI) to optimize recipient survival…
2017 American Transplant Congress
Rituximab Desensitization (DES) and Alemtuzumab Induction Significantly Reduced EBV Viremia and Post-Transplant Lymphoproliferative Disorder (PTLD) in HLA-Sensitized (HS) Kidney Transplant Patients.
B.-H. Shin,¹ S. Ge,¹ J. Mirocha,² D. Thomas,¹ E. Rodriguez,¹ C. Chao,¹ O. Galera,¹ A. Vo,¹ J. Choi,¹ A. Peng,¹ J. Kahwaji,¹ S. Jordan,¹ M. Toyoda.¹
¹Transplant Immunology Laboratory and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Biostatistics Core, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA
Background: PTLD is a serious complication in KTx pts and is usually associated with EBV infection. Recent studies showed that rituximab treatment prior to Tx…
2017 American Transplant Congress
Circulating Donor-Specific Memory B Cells (mBc) Discriminates Kidney Transplant Patients with Histological Lesions of ABMR in Absence of Circulating DSA.
S. Luque,² M. Lúcia,⁴ M. Jarque,² E. Crespo,² E. Melilli,¹ J. Martorell,³ J. Cruzado,^1,2 J. Torras,^1,2 J. Grinyó,^1,2 O. Bestard.^1,2
¹Kidney Transplant Unit, Nephrology Department, Bellvitge University Hospital, Barcelona, Catalunya, Spain; ²Experimental Nephrology Laboratory, IDIBELL, Barcelona, Catalunya, Spain; ³Immunogenetics Laboratory, Hospital Clínic, Barcelona, Catalunya, Spain; ⁴Transplant Immunology, School of Medicine, Stanford
Chronic (c)ABMR is a main cause of immune-mediated kidney allograft loss. For its diagnosis, specific histological lesions together with presence of circulating donor-specific alloantibodies (DSA)…
2017 American Transplant Congress
Avoidance or Reduction of Rituximab Might Improve Clinical Outcomes in ABO-Incompatible Renal Transplantation: Advantages and Disadvantages of Rituximab.
M. Okada,¹ Y. Watarai,¹ K. Iwasaki,² K. Murotani,³ T. Hiramitsu,¹ M. Tsujita,¹ N. Goto,¹ S. Narumi,¹ T. Kobayashi.²
¹Transplant and Endocrine Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan; ²Renal Transplant Surgery, Aichi Medical University, Nagakute, Japan; ³Clinical Research Center, Aichi Medical University, Nagakute, Japan
BACKGROUNDPretransplant desensitization with rituximab has contributed to drastic improvements in ABO-incompatible renal transplantation (ABO-I). However, ABO-I outcomes are still worse than those of ABO-identical or…
2017 American Transplant Congress
KDPI Usefulness in Spain: A Comparison with Classical ECD/SCD.
C. Arias-Cabrales,¹ M. Pérez-Sáez,¹ D. Redondo,¹ A. Buxeda,¹ C. Burballa,¹ S. Bermejo,¹ A. Sierra,¹ M. Mir,¹ A. Burón,² A. Zapatero,³ M. Crespo,¹ J. Pascual.¹
¹Nephrology, Hospital del Mar, Barcelona, Spain; ²Epidemiology and Evaluation, Hospital del Mar, Barcelona, Spain; ³Intensive Care Medicine, Hospital del Mar, Barcelona, Spain
Kidney donor shortage requires an expansion in selection criteria and objective tools to minimize discarded organs. Easy donor pretx variables such as age, standard/expanded criteria…
2017 American Transplant Congress
Post-Transplant Urinary Transglutaminase 2 Is a Potent Biomarker to Predict Kidney Allograft Inflammation or Fibrosis.
S. Shin,¹ Y.-M. Wee,¹ M. Choi,¹ Y. Cho,² H. Go,² Y. Kim,¹ D. Han.¹
¹Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; ²Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Transglutaminase type 2 (TG2) is an extracellular matrix crosslinking enzyme with a pivotal role in kidney fibrosis. We tested the hypothesis that quantification of urinary…
2017 American Transplant Congress
Course and Outcome of Renal Transplant Recipients Admitted to the Intensive Care Unit (ICU): Long Term Follow-Up.
A. El-Agroudy,¹ A. Alqahtani,¹ B. Dandi,² E. Farid,² A. Alaradhi.²
¹Medicine, Arabian Gulf University, Manama, Bahrain; ²Nephrology, Salmaniya Medical Complex, Manama, Bahrain
Background. The goal of this study was to evaluate the course and outcome of renal transplant recipients admitted to ICU and to analyze factors determining…
2017 American Transplant Congress
Poor Predictability of Quantiferon-TB Assay in Recipients and Donors for Tuberculosis Development After Kidney Transplantation in an Intermediate-TB-Burden Country.
J. Yang,¹ J. Ryu,¹ J. Jang,² J.-G. Lee,² C. Ahn.¹
¹Transplantation Center, Seoul National University Hospital, Seoul, Republic of Korea; ²Transplantation Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
Background. Tuberculosis (TB) is a common opportunistic infection after kidney transplantation (KT). Quantiferon-TB Gold In-Tube test (QFT) is widely used for assessing latent TB; however,…